Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

3/31/25 8:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $BDTX alert in real time by email

CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:

24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025
Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025

Webcasts will be available at the start of the presentations on the investor relations section of the Company's website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:

[email protected]

For Media:

[email protected]

Get the next $BDTX alert in real time by email

Recent Analyst Ratings for

$BDTX

Date	Price Target	Rating	Analyst
7/31/2024	$20.00	Outperform	Raymond James
7/14/2023		Overweight	Piper Sandler
6/30/2023	$2.00 → $10.00	Hold → Buy	Stifel
6/28/2023	$11.00	Neutral → Buy	H.C. Wainwright
6/27/2023	$10.00	Neutral → Outperform	Wedbush
3/29/2022		Outperform → Neutral	Wedbush
3/22/2022		Buy → Neutral	H.C. Wainwright
9/30/2021	$10.00	Hold	Stifel

More analyst ratings

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Chat with this insight

Recent Analyst Ratings for
$BDTX

$BDTX
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form S-8 filed by Black Diamond Therapeutics Inc.

$BDTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

$BDTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Behbahani Ali was granted 7,646 shares, increasing direct ownership by 12% to 70,980 units (SEC Form 4)

Director Raman Prakash was granted 6,848 shares, increasing direct ownership by 68% to 16,993 units (SEC Form 4)

Large owner Biotech Growth N V sold $11,997,749 worth of shares (5,784,292 units at $2.07), decreasing direct ownership by 68% to 2,733,547 units (SEC Form 4)

$BDTX
Leadership Updates

Live Leadership Updates

$BDTX
Financials

Live finance-specific insights

Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

Black Diamond Therapeutics Announces Changes to Board of Directors

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

$BDTX
Press Releases

Fastest customizable press release news feed in the world